Figure 1From: Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population Model schematic. Diagrammatic view of the model structure comprising three main health states: Stable, Response and Progression. (FN: febrile neutropenia; AE: adverse event)Back to article page